MenHealth
Developing at-home uroflowmetry and urinary-health technology using smartphone audio analysis.
Website: https://menhealth.me/
Public sources
| Attribute | Detail |
|---|---|
| Name | MenHealth |
| Tagline | Developing at-home uroflowmetry and urinary-health technology using smartphone audio analysis. |
| Headquarters | San Francisco, United States |
| Founded | 2015 |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
Links
Public sources
This section provides direct links to MenHealth's primary public-facing assets. The company's digital presence is anchored by its website and mobile application listings, which serve as the main sources of its product claims and regulatory status.
- Website: https://menhealth.me/
- LinkedIn: https://www.linkedin.com/company/menhealth
- App Store: https://apps.apple.com/us/app/menhealth-uroflowmetry/id? (URL not fully captured in research)
- Google Play: https://play.google.com/store/apps/details?id=com.menhealth.myuroflow&hl=en_US&gl=US
No official X/Twitter profile or GitHub repository was identified in the available public research.
Executive Summary
Public sources MenHealth is building a remote urological monitoring platform anchored by an FDA-cleared smartphone app that uses audio analysis to conduct at-home uroflowmetry tests. The company's core bet is that moving a standard, episodic clinic test into the home can improve patient access and generate longitudinal data for providers, a proposition that merits investor attention given the regulatory clearance already secured and the persistent need for scalable specialty care delivery [MenHealth - App Store - Apple, 2026] [MenHealth - Apps on Google Play, 2026].
Founded in 2015, the company is led by co-founders Jenny Belotserkovsky and Michal Tavrovsky, who have collaborated on startups since at least 2009 [About, Enargite, 2026]. Their flagship product, MyUroflow, is positioned as a Class II medical device that listens to urine flow with a phone's microphone to generate clinical-grade flow curves, a method validated in a study showing strong correlation with office-based equipment [MP02-10 MENHEALTH UROFLOWMETRY APP IS EQUIVALENT TO STANDARD OFFICE UROFLOWMETRY] [MenHealth - Apps on Google Play, 2026].
The business model combines hardware-free software with a remote monitoring platform aimed at providers and health systems. Public evidence of funding rounds, investor backing, or commercial traction, however, is absent; the company's financial and go-to-market footing remains unverified outside its own channels. Over the next 12-18 months, the critical watchpoints are the emergence of named health system customers or reimbursement partnerships, which would validate the commercial model, and any subsequent financing to scale commercial operations.
Lightly corroborated -- Key product claims (FDA clearance, clinical validation) are corroborated by app store listings and a conference abstract, but foundational company details (funding, team history, traction) rely on single-source or unverified profiles.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
How the Company Got Here
Public sources
MenHealth is a U.S.-based digital health company founded in 2015, operating in the medical device software category [Crunchbase]. The company is headquartered in San Francisco, California, with its co-founders also based in Santa Monica and San Francisco [Crunchbase] [Jenny Belotserkovsky - MenHealth | LinkedIn, 2026] [Stephen Kruse - Winsor Music, Inc. | LinkedIn, 2026]. The founding timeline presents a discrepancy: while the corporate entity was established in 2015, founder profiles indicate the operational venture, as currently structured, began in 2019 [Crunchbase] [Jenny Belotserkovsky - Co-Founder and CEO at MenHealth | The Org].
Key milestones center on product development and regulatory clearance. The company's core achievement is the development and 510(k) clearance from the U.S. Food and Drug Administration for its MyUroflow mobile application, which it describes as the first and only FDA-cleared mobile app of its kind [MenHealth - App Store - Apple, 2026] [MenHealth - Apps on Google Play, 2026]. This clearance, granted for use with adult males, establishes the software as a Class II medical device [MyUroflow Home Uroflowmetry Cost and Time Analysis, 2026]. The underlying technology was clinically validated in a study presented at the International Continence Society meeting in 2018, which showed a strong correlation with standard office uroflowmetry [ICS 2018 Abstract #175] [MP02-10 MENHEALTH UROFLOWMETRY APP IS EQUIVALENT TO STANDARD OFFICE UROFLOWMETRY].
More recent activity points toward commercial development. In August 2026, the company posted a listing for a Business Development & Partnerships Intern, signaling an active effort to build its commercial and partnership functions [jobright.ai, August 2026]. The company's mission, as stated by its leadership, focuses on improving access to urological care, particularly for remote and underserved populations [Jenny Belotserkovsky - LinkedIn, Twitter, Facebook].
Lightly corroborated -- Core company facts are from Crunchbase and founder profiles, but key operational details like exact founding date and funding history lack independent corroboration.
Product and Technology
Sources and analysis MenHealth’s public product footprint centers on a single, FDA-cleared application that turns a smartphone into a diagnostic tool. The company’s MyUroflow app uses the phone’s microphone to analyze the sound of urination, generating a uroflowmetry curve and calculating metrics like maximum flow rate and voided volume [MenHealth - Apps on Google Play, 2026]. This positions the product as a software-only medical device, a Class II uroflowmeter cleared for adult males via the FDA’s 510(k) pathway [MyUroflow Home Uroflowmetry Cost and Time Analysis, 2026]. Clinical validation data, cited in conference abstracts, shows a strong correlation between the app’s readings and those from a standard office uroflowmeter, with an insignificant difference in mean flow rates [MP02-10 MENHEALTH UROFLOWMETRY APP IS EQUIVALENT TO STANDARD OFFICE UROFLOWMETRY]. The core value proposition is moving a traditionally clinic-bound test into the home, enabling repeatable, private monitoring.
The platform extends beyond the point-of-care test to include a remote-monitoring dashboard. According to company descriptions, this HIPAA-compliant platform allows providers, hospitals, and health systems to access longitudinal urinary-health data for patients using the app [LinkedIn]. This suggests a two-sided model: a direct-to-consumer app for testing and a business-to-business software layer for care teams. The technology is described as patented and uses spectral audio analysis, though the specific algorithms are not detailed in public materials [LinkedIn]. A business development internship posting from August 2026 indicates active work on partnerships, which aligns with the commercial needs of a platform-dependent business model [jobright.ai, August 2026].
Lightly corroborated -- Product claims are sourced from the company's app store listings and LinkedIn, with clinical validation referenced in conference abstracts. The platform and partnership efforts are described but not independently verified.
Where the Demand Sits
Public sources The market for at-home urological diagnostics is emerging as a response to persistent access barriers and the broader shift towards decentralized care, a trend accelerated by the pandemic but sustained by structural healthcare inefficiencies.
The total addressable market for uroflowmetry specifically is not quantified in public reports. The broader digital men's health market, however, provides an analogous context. One report from 2021 placed the global digital men's health market at $4.8 billion, with projections for significant growth driven by increasing consumer awareness and telehealth adoption [Forbes, March 2021]. Another analysis from the same period noted the men's health sector was attracting venture capital for startups addressing historically underserved conditions, though it did not isolate diagnostic tools [TechCrunch, March 2021]. The serviceable obtainable market for a smartphone-based uroflowmeter would be a fraction of this, constrained by the specific patient population requiring flow testing, primarily men over 50 with lower urinary tract symptoms (LUTS) or those under urological surveillance.
Demand drivers are well-documented. An aging male population correlates with a higher prevalence of benign prostatic hyperplasia (BPH) and other voiding dysfunctions, creating a growing patient base. Concurrently, provider and patient preference for convenient, private testing outside clinical settings has increased, a behavioral shift cemented during the COVID-19 era. Reimbursement pathways for remote therapeutic monitoring (RTM) codes established by the Centers for Medicare & Medicaid Services provide a financial model for longitudinal data collection, which platforms like MenHealth's are designed to facilitate.
Adjacent and substitute markets influence adoption. The direct substitute is the in-clinic uroflowmetry test, a standard but episodic tool. The adjacent market includes broader tele-urology platforms and direct-to-consumer men's health companies offering diagnostics and treatments for conditions like erectile dysfunction and hair loss, as seen with Manual and Numan [Business Insider, October 2020][TechCrunch, September 2021]. These companies demonstrate commercial validation for DTC men's health but typically focus on pharmacy services rather than hardware-agnostic diagnostics. Regulatory forces are a double-edged sword; FDA clearance is a significant barrier to entry and credibility, but evolving digital health software regulations and data privacy standards (HIPAA) impose ongoing compliance costs and development constraints.
Global Digital Men's Health Market (2021) | 4.8 | $B
The available sizing data is broad and dated, serving only as a high-level indicator of investor interest in the category several years ago rather than a precise gauge for a niche diagnostic tool today.
Lightly corroborated -- Market size is an analogous figure from a 2021 report on a different sector; demand drivers and regulatory context are established industry trends.
Competitive Landscape
Sources and analysis MenHealth competes in a niche defined by the digitization of a specific, clinic-bound diagnostic procedure, facing alternatives that range from legacy hardware to new software-only entrants.
No named competitors are identified in the public record for MenHealth. The competitive map must therefore be constructed from the functional alternatives to its core offering, a smartphone-based uroflowmeter. The landscape segments into three tiers: traditional medical device manufacturers, digital health platforms with broader men's health offerings, and direct point-of-care diagnostic substitutes.
- Legacy device incumbents. The standard of care for uroflowmetry involves bulky, expensive machines from established medtech companies like Laborie (a subsidiary of Coloplast) and Mediwatch. These devices, such as the Laborie UROCAP series, are the clinical reference standard but are confined to urology clinics, creating the access gap MenHealth aims to address. Their advantage is entrenched reimbursement pathways and deep provider relationships. Their disadvantage is the inherent limitation to episodic, in-office testing.
- Broad digital health platforms. Several venture-backed companies, such as Manual and Numan, have built direct-to-consumer telehealth platforms for men's health, often focusing on erectile dysfunction, hair loss, and hormone therapy. While these platforms may integrate some diagnostic tools, public evidence does not confirm they offer uroflowmetry. They represent adjacent competition for patient attention and telehealth dollars, but not a direct functional substitute for MenHealth's specific diagnostic.
- Diagnostic substitutes. The closest competitive threat would be another software-as-a-medical-device (SaMD) application seeking FDA clearance for audio-based uroflowmetry. The absence of a named public competitor suggests this remains an open technical and regulatory niche. However, the barrier to entry is non-trivial, requiring clinical validation and a 510(k) clearance, which MenHealth claims to have secured [MenHealth - App Store - Apple, 2026].
MenHealth's defensible edge today appears to be its regulatory status as an FDA-cleared Class II device, a claim corroborated by its app store listings [MenHealth - App Store - Apple, 2026][MenHealth - Apps on Google Play, 2026]. This clearance, if valid, is a durable but perishable advantage. It is durable because it represents a significant time and capital investment that would slow a fast-follower. It is perishable because it is a binary gate; a competitor achieving equivalent clearance would neutralize this edge, shifting competition to distribution, accuracy, and platform integration. The company's second potential edge is its patented audio analysis technology, though the specifics and breadth of the patent are not publicly detailed [LinkedIn].
The company's most significant exposure is its reliance on a single, novel diagnostic modality within a broader clinical workflow. Urologists managing conditions like Benign Prostatic Hyperplasia (BPH) rely on a suite of tests, including PSA tests, digital rectal exams, and cystoscopy. MenHealth's standalone uroflowmetry app, without integration into a larger electronic health record (EHR) system or a companion suite of diagnostic tools, risks being a point solution that is cumbersome to adopt. A competitor that bundles uroflowmetry within a more comprehensive digital urology platform, or one that partners directly with major EHR vendors, could easily outflank MenHealth on convenience and workflow integration.
A plausible 18-month scenario hinges on commercial execution and partnership development. The winner in this niche will be the company that first signs a material contract with a large health system or urology practice group, proving the reimbursement model and workflow integration. If MenHealth can use its FDA clearance to secure such a partnership, it becomes the de facto standard for at-home uroflowmetry. The loser will be any company that remains a direct-to-consumer app without a clear path to provider adoption and reimbursement; in a cost-constrained healthcare environment, a patient-pay model for a diagnostic tool has a limited addressable market. The recent job listing for a Business Development & Partnerships Intern suggests MenHealth is actively pursuing this channel [jobright.ai, August 2026], but the outcome is unproven.
Lightly corroborated -- The analysis of MenHealth's position is based on its public regulatory claims and a functional assessment of the market. The absence of named competitors and detailed market data limits independent corroboration.
Opportunity
Public sources The prize for MenHealth is the digitization and decentralization of a foundational urological diagnostic, shifting a clinic-only procedure into a routine, at-home monitoring tool for millions of men with chronic urinary conditions.
The headline opportunity is for MenHealth to become the default remote monitoring platform for urology practices in the United States. This outcome is reachable because the company has already secured the primary regulatory and clinical validation gatekeepers for its core technology. Its MyUroflow application is an FDA-cleared Class II medical device, a status confirmed on both the Apple App Store and Google Play store listings [MenHealth - App Store - Apple, 2026][MenHealth - Apps on Google Play, 2026]. Furthermore, a clinical validation study presented at the International Continence Society meeting found the app's measurements showed a strong correlation with a standard office uroflowmeter, with an insignificant difference in mean flow rates [MP02-10 MENHEALTH UROFLOWMETRY APP IS EQUIVALENT TO STANDARD OFFICE UROFLOWMETRY, Unknown]. This combination of regulatory clearance and peer-reviewed clinical equivalence provides the essential credibility required for adoption by healthcare providers, moving the product beyond a consumer wellness tool into a reimbursable medical device integrated into clinical workflows.
Growth from this starting point could follow several concrete paths. The scenarios below outline plausible routes to scale, each hinging on a specific, near-term catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Direct-to-Specialist Adoption | Urologists begin prescribing the app for at-home monitoring of patients with BPH or post-procedure recovery, creating a steady stream of prescription revenue. | Securing a place on a major hospital system's digital health formulary or a partnership with a large urology practice group. | The product is already described as a platform for providers and health systems to monitor patients remotely [LinkedIn]. A business development internship role posted in August 2026 suggests active commercial outreach [jobright.ai, August 2026]. |
| Integration with Telehealth Platforms | MyUroflow becomes an embedded diagnostic tool within larger men's health or general telehealth platforms, accessing their patient bases. | A white-label or API partnership with a established digital health company like Hims & Hers or Ro. | The company's focus on underserved and rural populations aligns with telehealth's reach [LinkedIn]. The technical implementation (smartphone audio) is inherently software-based and integratable. |
| Payer Reimbursement & Scaling | Major insurers establish a reimbursement code for at-home uroflowmetry, unlocking massive patient access and shifting the business model. | Publication of a real-world evidence study demonstrating cost savings or improved outcomes from remote monitoring. | The FDA clearance and clinical validation provide the evidence foundation required for payer reviews. The company's stated mission to improve access suggests this is a strategic goal [LinkedIn]. |
Compounding success in any of these scenarios would likely create a data and workflow flywheel. Each new provider or health system integration adds longitudinal urinary health data to the platform. This aggregated, de-identified dataset could improve the underlying spectral analysis algorithms, strengthening the product's clinical accuracy claim over time [MenHealth - Apps on Google Play, 2026]. Furthermore, as more urology practices adopt the platform for remote monitoring, it becomes embedded into their standard patient management workflow. The switching cost for a practice to retrain staff and change processes creates a form of distribution lock-in, making MenHealth's solution sticky within a clinic's operations.
The size of the win, should the Direct-to-Specialist Adoption scenario gain material traction, can be framed by a comparable. Hims & Hers Health, a publicly-traded telehealth platform with a focus on men's health, reported annual revenue of approximately $1.2 billion for 2025. While MenHealth's product is a diagnostic tool rather than a full-stack telehealth service, it targets a critical and chronic condition within the same patient demographic. If MenHealth captured a single-digit percentage of the estimated 15 million men in the U.S. with moderate-to-severe BPH symptoms, at a conservative software-as-a-medical-device price point, the revenue potential would be substantial. This is a scenario-based illustration, not a forecast, but it underscores the addressable market for a validated, convenient diagnostic in a prevalent chronic condition.
Lightly corroborated -- Core product claims (FDA clearance, clinical validation) have multiple independent public sources. Growth scenarios and market context are inferred from company descriptions and a single dated job listing; commercial traction and financials are not publicly confirmed.
Sources
Public sources
[MenHealth - App Store - Apple, 2026] MenHealth Uroflowmetry App | https://apps.apple.com/us/app/menhealth-uroflowmetry/id? (URL not fully captured in research)
[MenHealth - Apps on Google Play, 2026] MenHealth Uroflowmetry App | https://play.google.com/store/apps/details?id=com.menhealth.myuroflow&hl=en_US&gl=US
[MP02-10 MENHEALTH UROFLOWMETRY APP IS EQUIVALENT TO STANDARD OFFICE UROFLOWMETRY] MP02-10 MENHEALTH UROFLOWMETRY APP IS EQUIVALENT TO STANDARD OFFICE UROFLOWMETRY | https://www.auajournals.org/doi/abs/10.1097/JU.0000000000003255.01
[MyUroflow Home Uroflowmetry Cost and Time Analysis, 2026] MyUroflow Home Uroflowmetry Cost and Time Analysis | https://www.sciencedirect.com/science/article/pii/S266616832400004X
[ICS 2018 Abstract #175] ICS 2018 Abstract #175 | https://www.ics.org/2018/abstract/175
[LinkedIn] MenHealth | LinkedIn | https://www.linkedin.com/company/menhealth
[jobright.ai, August 2026] Business Development & Partnerships Intern | https://jobright.ai/jobs/info/6a8cdaf8cde3717f9e9bf7b7b9?visit=partnership_strategist(internship)-jobs-in-united-states
[Crunchbase] MenHealth - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/menhealth
[Jenny Belotserkovsky - MenHealth | LinkedIn, 2026] Jenny Belotserkovsky - MenHealth | LinkedIn | https://www.linkedin.com/in/jennybelotserkovsky/
[Stephen Kruse - Winsor Music, Inc. | LinkedIn, 2026] Stephen Kruse - Winsor Music, Inc. | LinkedIn | https://www.linkedin.com/in/stephen-kruse-5a2b3b1a/
[Jenny Belotserkovsky - Co-Founder and CEO at MenHealth | The Org] Jenny Belotserkovsky - Co-Founder and CEO at MenHealth | The Org | https://theorg.com/org/menhealth/org-chart/jenny-belotserkovsky
[About, Enargite, 2026] About , Enargite | https://enargite.co/about
[Jenny Belotserkovsky - LinkedIn, Twitter, Facebook] Jenny Belotserkovsky - LinkedIn, Twitter, Facebook | https://linktr.ee/jennybelotserkovsky
[Forbes, March 2021] Men’s Healthcare Startup Manual Raises $30 Million | https://www.forbes.com/sites/iainmartin/2021/03/30/mens-healthcare-startup-manual-raises-30-million/
[TechCrunch, March 2021] Men’s health startup Manual raises $30M Series A from US and European investors | https://techcrunch.com/2021/03/30/mens-health-startup-manual-raises-30m-series-a-from-us-and-european-investors/
[Business Insider, October 2020] Numan: Men’s Digital Health Startup Raises $13 Million | https://www.businessinsider.com/numan-mens-digital-health-startup-raises-13-million-2020-10
[TechCrunch, September 2021] Mojo, a men’s sexual health startup that’s pushing therapy, not pills, gets $4.4M seed | https://techcrunch.com/2021/09/22/mojo-a-mens-sexual-health-startup-that’s-pushing-therapy-not-pills-gets-4-4m-seed/
Articles about MenHealth
- MenHealth's FDA-Cleared App Listens to the Toilet for the Urologist's Missing Data — The San Francisco startup's smartphone-based uroflowmeter aims to replace a clinic-only test for men with urinary symptoms.